Lawrence Severt

2.5k total citations · 2 hit papers
35 papers, 945 citations indexed

About

Lawrence Severt is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, Lawrence Severt has authored 35 papers receiving a total of 945 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 9 papers in Pathology and Forensic Medicine and 9 papers in Neurology. Recurrent topics in Lawrence Severt's work include Migraine and Headache Studies (26 papers), Olfactory and Sensory Function Studies (8 papers) and Botulinum Toxin and Related Neurological Disorders (6 papers). Lawrence Severt is often cited by papers focused on Migraine and Headache Studies (26 papers), Olfactory and Sensory Function Studies (8 papers) and Botulinum Toxin and Related Neurological Disorders (6 papers). Lawrence Severt collaborates with scholars based in United States, United Kingdom and Denmark. Lawrence Severt's co-authors include Richard B. Lipton, Joel M. Trugman, Michelle Finnegan, Rosa Miceli, Jessica Ailani, Peter J. Goadsby, Hua Guo, Kaifeng Lu, Sung Yun Yu and Susan Bressman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Neurology.

In The Last Decade

Lawrence Severt

33 papers receiving 919 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atogepant for the Preventive Treatment of Migraine

2021 194 citations Jessica Ailani, Richard B. Lipton et al. New England Journal of Medicine profile →
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

2023 75 citations Patricia Pozo‐Rosich, Jessica Ailani et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lawrence Severt United States	15	617	409	284	273	120	35	945
Luisa Fofi Italy	21	698 1.1×	348 0.9×	305 1.1×	154 0.6×	175 1.5×	54	1.0k
Ryan Cady United States	10	402 0.7×	293 0.7×	462 1.6×	288 1.1×	54 0.5×	16	816
Roshni Ramachandran United States	17	531 0.9×	198 0.5×	386 1.4×	163 0.6×	141 1.2×	28	1.0k
R. Cerbo Italy	14	618 1.0×	349 0.9×	238 0.8×	128 0.5×	56 0.5×	44	770
Krista I Roon Netherlands	7	792 1.3×	545 1.3×	355 1.3×	81 0.3×	58 0.5×	8	891
L. L. Thomsen Denmark	11	713 1.2×	381 0.9×	300 1.1×	76 0.3×	151 1.3×	11	853
F. Michael Cutrer United States	14	583 0.9×	286 0.7×	141 0.5×	86 0.3×	313 2.6×	28	804
A. M. Rapoport United States	10	371 0.6×	275 0.7×	221 0.8×	109 0.4×	215 1.8×	12	732
Yannan Fang China	12	377 0.6×	210 0.5×	185 0.7×	92 0.3×	193 1.6×	15	897
András Király Hungary	16	287 0.5×	170 0.4×	123 0.4×	131 0.5×	112 0.9×	59	755

Countries citing papers authored by Lawrence Severt

Since Specialization

Citations

This map shows the geographic impact of Lawrence Severt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Severt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Severt more than expected).

Fields of papers citing papers by Lawrence Severt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Severt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Severt. The network helps show where Lawrence Severt may publish in the future.

Co-authorship network of co-authors of Lawrence Severt

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Severt. A scholar is included among the top collaborators of Lawrence Severt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Severt. Lawrence Severt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dodick, David W., Peter J. Goadsby, Todd J. Schwedt, et al.. (2023). Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. The Lancet. 402(10419). 2307–2316. 48 indexed citations

Pozo‐Rosich, Patricia, Jessica Ailani, Messoud Ashina, et al.. (2023). Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 402(10404). 775–785. 75 indexed citations breakdown →

Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2023). Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache The Journal of Head and Face Pain. 63(1). 79–88. 36 indexed citations

Schwedt, Todd J., Richard B. Lipton, Peter J. Goadsby, et al.. (2023). Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening Period (S41.009). Neurology. 100(17_supplement_2). 3 indexed citations

Dodick, David W., Peter J. Goadsby, Todd J. Schwedt, et al.. (2023). Ubrogepant for the Acute Treatment of Migraine When Administered During the Prodrome (Premonitory Phase): Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled, Crossover Study (S47.001). Neurology. 100(17_supplement_2). 5 indexed citations

Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2022). Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial (P1-2.001). Neurology. 98(18_supplement). 1 indexed citations

Klein, Brad, Rosa Miceli, Lawrence Severt, et al.. (2022). Evaluation of the Long-Term Safety and Tolerability of Oral Atogepant 60 Mg Once Daily for Preventive Treatment of Migraine: A Phase 3, 40-Week, Multicenter Extension to the Advance Trial (P3-2.001). Neurology. 98(18_supplement).

Dodick, David W., Debbie L. Hay, Christopher S. Walker, et al.. (2022). Decrease in Body Weight With Once-Daily Atogepant for the Preventive Treatment of Migraine: A Post Hoc Analysis (P1-2.002). Neurology. 98(18_supplement). 1 indexed citations

Blumenfeld, Andrew, Susan Hutchinson, Jelena Pavlović, et al.. (2022). Post-hoc Analysis of Safety in Phase 3 Atogepant ADVANCE Trial Participants with or without Cardiovascular Disease Risk Factors (P2-2.005). Neurology. 98(18_supplement). 1 indexed citations

10.

Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2021). Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine (2664). Neurology. 96(15_supplement). 5 indexed citations

11.

Dodick, David W., Patricia Pozo‐Rosich, Andrew Blumenfeld, et al.. (2021). Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine (1459). Neurology. 96(15_supplement). 3 indexed citations

12.

Blumenfeld, Andrew, Kerry Knievel, Aubrey Manack Adams, et al.. (2021). Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Advances in Therapy. 39(1). 692–705. 6 indexed citations

13.

Ashina, Messoud, SJ Tepper, Uwe Reuter, et al.. (2021). P.030 Long-term Safety and Tolerability of Atogepant 60 mg Following Once-Daily Dosing Over 1 Year for the Preventive Treatment of Migraine. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 48(s3). S28–S29. 2 indexed citations

14.

Ailani, Jessica, Richard B. Lipton, Peter J. Goadsby, et al.. (2021). Atogepant for the Preventive Treatment of Migraine. New England Journal of Medicine. 385(8). 695–706. 194 indexed citations breakdown →

15.

Ailani, Jessica, Andrew Blumenfeld, Michelle Finnegan, et al.. (2020). An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine (166). Neurology. 94(15_supplement). 9 indexed citations

16.

Trugman, Joel M., Jessica Ailani, Susan Hutchinson, et al.. (2020). Efficacy Is Maintained With Long-term Intermittent Use of Ubrogepant for the Acute Treatment of Migraine (111). Neurology. 94(15_supplement). 2 indexed citations

17.

Torres, Paola, Matthew Swan, William C. Nichols, et al.. (2016). Glucocerebrosidase enzyme activity in GBA mutation Parkinson’s disease. Journal of Clinical Neuroscience. 28. 185–186. 23 indexed citations

18.

Huang, Chaorui, Lisa Ravdin, Melissa J. Nirenberg, et al.. (2013). Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Computed Tomography Study. Dementia and Geriatric Cognitive Disorders. 35(3-4). 183–196. 79 indexed citations

19.

Saunders‐Pullman, Rachel, Matthew J. Barrett, Kaili Stanley, et al.. (2010). LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Movement Disorders. 25(15). 2536–2541. 52 indexed citations

20.

Saunders‐Pullman, Rachel, Carol A. Derby, Kaili Stanley, et al.. (2007). Validity of spiral analysis in early Parkinson's disease. Movement Disorders. 23(4). 531–537. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact